Evidence map›Paper›PMID 41680482›Full record

ArticleNature medicine2026

Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy.

Aarthi Talla, Joao L L C Azevedo, Muhammad Bilal Latif, Ana B Enriquez, Gabriela Pacheco Sanchez, Adam N Pelletier, Saswat Kumar Bal, Sangeeta Kumari, Viviane Schuch, Khader Ghneim and 17 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Aarthi Talla *Immunasyst, Phoenix, AZ, USA.
Joao L L C Azevedo *Pathology Advanced Translational Research Unit, Department of Pathology, Emory University, School of Medicine, Atlanta, GA, USA.
Muhammad Bilal LatifPathology Advanced Translational Research Unit, Department of Pathology, Emory University, School of Medicine, Atlanta, GA, USA.
Ana B EnriquezPathology Advanced Translational Research Unit, Department of Pathology, Emory University, School of Medicine, Atlanta, GA, USA.
Gabriela Pacheco SanchezDepartment of Biology, West Virginia University, Morgantown, WV, USA.
Adam N PelletierRPM Bioinfo Solutions, Montreal, Quebec, Canada.
Saswat Kumar BalSignios Biosciences, Inc., Foster City, CA, USA.
Sangeeta KumariTakara Bio USA, Inc., San Jose, CA, USA.
Viviane SchuchDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, USA.
Khader GhneimPathology Advanced Translational Research Unit, Department of Pathology, Emory University, School of Medicine, Atlanta, GA, USA.
Ajantha RhodesDepartment of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Frank MaldarelliHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3062-5250
Robert YarchoanHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3057-1395
Kathryn LurainDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Ramya RamaswamiHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-5709-4675
Elad SharonDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0044-9719
Bruce W HessFred Hutchinson Cancer Center, Seattle, WA, USA.
Leonard D'AmicoFred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-1143-7297
Javier Martinez-PicadoIrsiCaixa, Barcelona, Spain.ORCID http://orcid.org/0000-0002-4916-2129
Nicolas ChomontDepartment of Microbiology, Infectiology, and Immunology, Université de Montréal and Centre de Recherche du CHUM, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0001-9747-5018
Sharon R LewinDepartment of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-0330-8241
Steven G DeeksUniversity of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6371-747X
Steven P FlingFred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-6263-0153
Martin A CheeverFred Hutchinson Cancer Center, Seattle, WA, USA.
Thomas S UldrickFred Hutchinson Cancer Center, Seattle, WA, USA.
Ashish A SharmaPathology Advanced Translational Research Unit, Department of Pathology, Emory University, School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-9444-7046
Rafick-Pierre SekalyPathology Advanced Translational Research Unit, Department of Pathology, Emory University, School of Medicine, Atlanta, GA, USA. rafick.sekaly@emory.edu.ORCID http://orcid.org/0000-0002-7816-4828

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Reversing Immune Dysfunction for HIV-1 EradicationUM1AI164561 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Paula M Cannon · 2021 to 2026
$30.0M
MultiOMICS to uncover immune and virological mechanisms that drive HIV DNA decay, restore immune homeostasis, and promote HIV specific immunity in PWH receiving cell therapies.P01AI178376 · NIAID · EMORY UNIVERSITY · PI Rafick Pierre Sekaly · 2023 to 2026
$6.1M
NIAID NIH HHS P30 AI050409U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) P01AI178376U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1AI164561
6 · The paper itself

Abstract

Antiretroviral therapy (ART) suppresses HIV but does not eliminate the latent viral reservoir, which persists in programmed cell death protein 1 (PD-1)-expressing CD4

Indexed as

Antibodies, Monoclonal, HumanizedHIV-1HIV InfectionsImmunity, InnateNeoplasmsProgrammed Cell Death 1 ReceptorAdultCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansMaleMiddle AgedViral LoadVirus LatencyAntibodies, Monoclonal, HumanizedPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 Receptor

Identifiers

PMID41680482
PMCPMC12920136

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.